You don’t get a second chance when selling your dermatology practice.

And yet, every month we speak with dermatologists who’ve taken a meeting with a buyer “just to see what it’s worth,” responded to a cold email that “seemed legit,” or worse—signed an LOI without ever putting their practice on the open market.

On the surface, the numbers may look fair. The buyer sounds experienced. The process feels manageable. But behind the scenes? You’re operating on borrowed information, limited leverage, and someone else’s terms.

At TUSK, we advise dermatology practice owners across the country through high-stakes sales. And the single biggest variable in deal outcomes isn’t size, location, or even performance.

It’s whether the seller had the right representation.

Here’s what dermatologists risk when they try to sell unrepresented in 2025.

Limited Access to Buyers Means Leaving Value on the Table

You can’t create competitive tension with one buyer. When it comes to dermatology M&A, visibility equals leverage. The most successful dermatology practice sales start with a process.

There are dozens of active buyers in dermatology today, from national platforms to emerging PE-backed MSOs to regional roll-ups. Each comes with different strategies, cultures, and valuation methodologies. And yet, most unrepresented sellers end up speaking with only one or two.

The result? Zero leverage. No competitive pressure. And a final offer that reflects what the buyer wants to pay, not what the market would’ve paid if the practice had been properly positioned.

The Wrong Buyer Can Look Like the Right One

Most dermatology buyers in today’s market are professional, well-capitalized, and know what they’re looking for. But that doesn’t mean they’re the right partner for you, or that they’re valuing your practice based on its true potential.

We often see offers that:

• Use buyer-friendly EBITDA adjustments to drive the valuation lower
• Include earnouts or equity rollovers with unclear upside
• Don’t reflect the full potential of the practice in the hands of a strategic operator

But what’s missing is context. What would this practice be worth to other buyers? How would different groups structure the deal? What hidden concessions are tucked into that LOI?

These aren’t bad actors. They’re just operating in a system where they hold all the cards, unless someone is sitting on your side of the table.

A seasoned dermatology broker like TUSK doesn’t just get you in front of more buyers—they help you evaluate offers through the lens of fit, structure, and long-term alignment. Because selling your practice isn’t just about the number, it’s about who you’re partnering with for the next phase of your career.

Dermatology Valuation Is Not One-Size-Fits-All

Understanding how to evaluate the value of your dermatology practice requires benchmarking it against other deals, knowing which dermatology buyers are paying premiums, and understanding how each variable affects your dermatology valuation multiple. Not all EBITDA is treated equally. Not all structures deliver the same outcome.

We’re in active conversations with buyers every week. We know what they’re paying. We know what they’re prioritizing. And we know how to position your dermatology practice to get the highest possible outcome on both dollars and deal terms.

At TUSK, we help sellers break down the factors that truly drive dermatology valuation multiples.

Key Drivers of Dermatology Valuation:

• Payor mix and reimbursement rates– How your commercial, Medicare, and private pay revenue blend impacts perceived stability.
• Provider structure– Whether the owner-physician is key to operations or has built a scalable provider team.
• Case mix and services offered– Practices with high-margin cosmetic services often command stronger valuation multiples.
• Geographic location– Demand from private equity and MSOs varies by region, population growth, and saturation.
• Referral sources and revenue concentration– A diversified referral base signals lower risk to buyers.
• Back-office infrastructure– Sophisticated systems, EMRs, and staff can reduce buyer overhead and boost value.
• Growth trajectory– Buyers pay premiums for upward momentum and clear expansion potential.
• Risk exposure– Heavy dependence on one provider or one payor can lower your multiple.

Dermatology Practice Sales in 2025 Require More Than a Good Offer

Selling a dermatology practice is not a side project. It’s a full-time job layered on top of your existing clinical responsibilities. Between diligence requests, deal team calls, legal review, working capital adjustments, QofE prep, and renegotiating lease terms, it’s easy to get buried in a process you’ve never done before.

The question isn’t “can you manage it?” The question is: what gets missed when you try?

We’ve seen it all—sellers who unknowingly signed away non-competes that limited their career options. Earnouts, they thought, were guaranteed. Equity, they didn’t realize, was illiquid. When you don’t know what’s negotiable, you lose your chance to negotiate it.

You Only Sell Once. Do It Right.

The dermatology M&A market continues to be very active in 2025. Private equity continues to find the industry attractive, new platforms are being formed, and buyers are hungry for deals. But just because capital is flowing doesn’t mean outcomes are guaranteed.

Whether your practice is doing $2M or $20M, the difference between a good deal and a great one comes down to process, positioning, and protection.

Don’t mistake an unsolicited offer for an opportunity. And don’t go to market alone.

If you’re considering a sale, or simply want to understand your options, let’s have a confidential conversation. TUSK has worked alongside many dermatology practice owners nationally to help them outline their exit strategy to align with their financial, emotional, and operational goals.

Meet the Author: Joshua Swearingen, Director 

Josh has over 15 years of leadership experience in the dental and healthcare industry, most recently serving as the CEO for Vesper Alliance, a DSO located in Cincinnati and Columbus, OH. Prior to that Josh was Director of Corporate Development for American Dental Partners and quarterbacked several of their largest transactions during his tenure there. Josh received his B.S from THE Ohio State University.

Meet Joshua Swearingen